

# **CRISPR-Cas Gene Editing in Cancer: A Transformative Frontier in Clinical Oncology**

**Michael R. Ellington\***

Department of Molecular Oncology, University of Westbridge, United Kingdom

## **Opinion**

**Received:** 02-Jun-2025, Manuscript No. rct-25-189151; **Editor assigned:** 04-Jun-2025, Pre-QC No. rct-25-189151 (PQ); **Reviewed:** 18-Jun-2025, QC No rct-25-189151; **Revised:** 23-Jun-2025, Manuscript No. rct-25-189151 (R); **Published:** 30-Jun-2025, DOI: 10.4172/rct.9.010

### **\*For Correspondence**

Michael R. Ellington, Department of Molecular Oncology, University of Westbridge, United Kingdom

**E-mail:** michael.ellington@utbs-west-bridge.edu

**Citation:** Michael R. Ellington, CRISPR-Cas Gene Editing in Cancer: A Transformative Frontier in Clinical Oncology. Rep Cancer Treat. 2025.9.010.

**Copyright:** © 2025 Michael R. Ellington, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

cells.

Originally discovered as a bacterial adaptive immune system, CRISPR-Cas9 has been repurposed as a powerful genome engineering tool. Its application in oncology has rapidly expanded from experimental cancer models to preclinical and early clinical therapeutic strategies. Recent literature suggests that CRISPR-based interventions may be used to disrupt oncogenic mutations, enhance anti-tumor immunity, and engineer immune cells with superior tumor-killing capacity.

### **Mechanism of CRISPR in Cancer Gene Editing**

CRISPR-Cas systems function through a guide RNA (gRNA) that directs the Cas enzyme to a specific DNA sequence. Once bound, Cas9 introduces a double-strand break, which is repaired by cellular mechanisms—either non-homologous end joining (NHEJ) or homology-directed repair (HDR). This allows gene disruption, correction, or insertion.

### **In oncology, these mechanisms are leveraged to:**

- Knock out oncogenes (e.g., KRAS, MYC)
- Restore tumor suppressor genes (e.g., TP53)
- Modify immune checkpoint genes

## **ABSTRACT**

CRISPR-Cas gene editing has emerged as one of the most revolutionary technologies in modern biomedical science, offering unprecedented precision in manipulating the human genome. In oncology, CRISPR has reshaped approaches to cancer modeling, diagnosis, and therapy by enabling targeted modification of oncogenes, tumor suppressor genes, and immune pathways. This opinion article explores the evolving role of CRISPR in clinical oncology, highlighting its therapeutic promise, translational barriers, ethical considerations, and future prospects. While early clinical trials show encouraging safety and efficacy signals, significant challenges—including off-target effects, delivery limitations, tumor heterogeneity, and regulatory constraints—continue to restrict widespread clinical adoption. The article argues that CRISPR is not a standalone cure but a foundational enabling platform that, when integrated with immunotherapy and precision medicine, could redefine cancer treatment paradigms.

## **Keywords**

CRISPR-Cas9, cancer therapy, genome editing, oncology, immunotherapy, gene knockout, tumor microenvironment, precision medicine, CAR-T cells, clinical trials

## **INTRODUCTION**

Cancer remains one of the leading causes of mortality worldwide despite advances in chemotherapy, radiotherapy, and immunotherapy. Traditional treatment approaches often suffer from limited specificity and severe systemic toxicity. The emergence of CRISPR-Cas technology has introduced a paradigm shift by enabling precise, programmable editing of DNA sequences within living

- Engineer immune effector cells for enhanced cytotoxicity

Advanced CRISPR variants such as base editing and prime editing further improve precision by reducing double-strand breaks and minimizing genomic instability.

## **Applications of CRISPR in Cancer Research**

### **1. Cancer Modeling**

CRISPR enables rapid generation of genetically engineered cell lines and animal models that mimic human cancers. This has significantly improved the understanding of tumor initiation, progression, and metastasis.

### **2. Target Identification**

High-throughput CRISPR screens allow researchers to identify essential genes for tumor survival and drug resistance, facilitating novel therapeutic target discovery.

### **3. Immuno-oncology Enhancement**

CRISPR is widely used to engineer T cells, natural killer (NK) cells, and CAR-T cells with improved anti-tumor activity. For example, deletion of immune checkpoint regulators enhances immune activation against tumors.

## **CRISPR in Cancer Therapy**

### **1. Gene Knockout Strategies**

CRISPR can disrupt oncogenic drivers, thereby inhibiting tumor growth. This approach is particularly relevant in cancers driven by single dominant mutations.

### **2. Immune Cell Engineering**

One of the most promising applications is ex vivo modification of immune cells. Clinical trials have demonstrated that CRISPR-edited tumor-infiltrating lymphocytes can show enhanced tumor recognition and killing ability with acceptable safety profiles in early studies.

### **3. Direct Tumor Targeting**

Experimental approaches involve delivering CRISPR systems directly into tumors using viral or nanoparticle vectors. These methods aim to selectively eliminate cancer-driving genes in situ.

## **Clinical Progress and Evidence**

Early-phase clinical trials indicate that CRISPR-based therapies are generally safe and can produce measurable anti-tumor responses in certain patients. Some studies report disease stabilization and even complete remission in advanced cancers following CRISPR-edited immune cell therapy.

However, these findings remain preliminary, and most evidence is restricted to small cohorts and highly controlled experimental settings.

## **Advantages of CRISPR in Oncology**

- High genomic precision
- Programmable targeting capability
- Ability to multiplex gene editing
- Integration with immunotherapy platforms
- Potential for personalized medicine

## **Limitations and Challenges**

### **1. Off-Target Effects**

Unintended genetic modifications remain a major concern, potentially leading to genotoxicity or secondary malignancies.

### **2. Delivery Barriers**

Efficient and safe delivery of CRISPR components into tumor cells remains technically challenging.

### **3. Tumor Heterogeneity**

Cancer genomes are highly variable, reducing the effectiveness of single-target approaches.

### **4. Ethical and Regulatory Issues**

Germline editing concerns, long-term safety unknowns, and regulatory inconsistencies hinder clinical translation.

## **Ethical Considerations**

CRISPR raises profound ethical questions, particularly regarding human genome modification. While somatic editing for cancer therapy is broadly considered acceptable, concerns persist regarding unintended consequences, consent in terminal patients, and equitable access to expensive gene therapies.

## **Future Perspectives**

**The future of CRISPR in oncology lies in integration rather than isolation. Promising directions include:**

- CRISPR-enhanced CAR-T and NK cell therapies
- AI-guided genome editing design
- Nanoparticle-based delivery systems
- Combination with checkpoint inhibitors
- Personalized tumor-specific editing strategies

Next-generation CRISPR tools are expected to improve precision and reduce toxicity, potentially making gene editing a mainstream cancer therapy within the next decades.

## **CONCLUSION**

CRISPR-Cas gene editing represents a transformative innovation in clinical oncology, offering the ability to directly rewrite the genetic basis of cancer. While still in its developmental phase, its integration with immunotherapy and precision medicine could fundamentally alter cancer treatment strategies. However, significant scientific, technical, and ethical barriers must be overcome before CRISPR can transition from experimental promise to routine clinical practice. In this sense, CRISPR should be viewed not as a singular cure, but as a powerful enabling technology shaping the next era of oncology.

## **REFERENCES**

1. Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. *Nat Med.* 2021;27(1):44-56.
2. Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, et al. Personalized nutrition by prediction of glycemic responses using machine learning. *Cell.* 2021;163(5):1079-1094.
3. Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, et al. Human postprandial responses to food and potential for precision nutrition. *Nat Med.* 2022;28(5):1001-1012.
4. He J, Baxter SL, Xu J, Xu J, Zhou X, Zhang K. The practical implementation of artificial intelligence technologies in medicine. *Nat Med.* 2021;27(1):27-38.
5. Cavallo F, Morais A, Teixeira A, Fico G, Santini S, Zdravevski E, et al. Artificial intelligence and machine learning in nutrition research: A systematic review. *Nutrients.* 2023;15(4):987.